Roche Holding | ROG - Sales Revenues


Roche Holding reported CHF15.65B in Sales Revenues for its fiscal semester ending in December of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Alcon AG USD 2.7B 110M Dec/2025
Almirall EUR 547.63M 12.83M Dec/2025
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Bayer EUR 11.44B 1.78B Dec/2025
Biogen USD 2.28B 250M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Fresenius EUR 5.88B 400M Dec/2025
Fresenius Medical Care EUR 5.07B 180M Dec/2025
Galapagos EUR 900.82M 835.52M Dec/2025
Genmab DKK 1.06B 36M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
GRIFOLS EUR 1.98B 110M Dec/2025
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 5.25B 70M Dec/2025
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Orion EUR 695.3M 272.1M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Philips EUR 5.1B 797M Dec/2025
Recordati EUR 662M 37.65M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
UCB EUR 4.25B 764M Dec/2025